Skip to main content
. 2024 Feb 25;47(2):e24245. doi: 10.1002/clc.24245

Figure 2.

Figure 2

The cox regression analysis between the clinical parameters and survival in patients treated with endothelin receptor antagonist + phosphodiesterase 5 inhibitor + selexipag.